Source: Annual Congress 2006 - Clinical management of interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Ongen, H. Ikitimur, B. Musellim (Istanbul, Turkey). Etiologic factors in patients with systemic sclerosis. Eur Respir J 2006; 28: Suppl. 50, 654

Member's Comments

No comment yet.

Related content which might interest you: Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1701197; 10.1183/13993003.01197-2017 Year: 2018 The genetics of systemic sclerosis Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Survival and prognostic factors in progressive systemic sclerosis with lung involvement Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening Source: Eur Respir Rev 2011; 20: 270-276 Year: 2011 Clinical and laboratory features of systemic sclerosis with pulmonary involvement Source: Eur Respir J 2001; 18: Suppl. 33, 512s Year: 2001 Pulmonary involvement in systemic sclerosis Source: Eur Respir Monogr 2019; 86: 90-105 Year: 2019 Pulmonary hypertension in patients with lupus: Prevalence, etiology and risk factors Source: Annual Congress 2012 - Pulmonary circulation: clinical databases and registries Year: 2012 Pulmonary functions in systemic sclerosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Predictors of progression in systemic sclerosis patients with interstitial lung disease Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019 Year: 2020 Histology is not a prognostic indicator in patients with interstitial pneumonias associated with systemic sclerosis Source: Eur Respir J 2001; 18: Suppl. 33, 526s Year: 2001 Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1801745; 10.1183/13993003.01745-2018 Year: 2018 Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Pulmonary hypertension in systemic sclerosis: different phenotypes Source: Eur Respir Rev, 26 (145) 170056; 10.1183/16000617.0056-2017 Year: 2017 Hemodynamic phenotypes in systemic sclerosis patients screened for pulmonary hypertension – impact of the new PH-definition Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus Source: Eur Respir Rev 2011; 20: 277-286 Year: 2011 Autoantibodies to the surfactant protein D in patients with interstitial lung diseases associated with amyopathic dermatomyositis and systemic sclerosis Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Early outcomes of patients with systemic lupus erythematosus and antiphospholipid syndrome after pulmonary endarterectomy Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Disease course and outcome of progressive interstitial lung disease in systemic sclerosis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019